Table 4 Incremental Cost-Effectiveness Ratios Comparing SBRT versus sorafenib at the Base Case
From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Various cost | Sorafenib | SBRT |
|---|---|---|
QALYs (years) | 3.07 | 2.81 |
Incremental QALY gained (years) | 0.26 | - |
Lifetime cost (US$) | 2166,079.7 | 1,197,039.2 |
Incremental cost (NT$) | 969,041 | - |
Cost/effectiveness | 704,857.96 | 426,117.13 |
ICER (NT$) | 3,788,238 | |
Cost-effectiveness threshold (NT$) | 2,213,145 | |
Is SBRT cost-effective? | No | |